Shares of Lonza Group Ltd (OTCMKTS:LZAGY) have been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company.
LZAGY has been the subject of a number of analyst reports. Societe Generale reaffirmed a “buy” rating on shares of Lonza Group in a report on Thursday, July 29th. Credit Suisse Group reissued an “outperform” rating on shares of Lonza Group in a report on Wednesday, July 28th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Lonza Group in a report on Thursday, July 29th. Zacks Investment Research cut Lonza Group from a “buy” rating to a “hold” rating in a report on Friday, September 10th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Lonza Group in a research report on Wednesday, September 8th.
Shares of LZAGY traded up $2.96 during mid-day trading on Friday, reaching $77.96. The company had a trading volume of 47,798 shares, compared to its average volume of 80,013. Lonza Group has a 52-week low of $55.69 and a 52-week high of $86.31. The stock has a market capitalization of $58.06 billion, a P/E ratio of 59.97 and a beta of 0.62. The stock has a 50 day moving average of $80.39 and a two-hundred day moving average of $71.56.
Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. It operates through the following segments: Lonza Pharma Biotech & Nutrition and Lonza Specialty Ingredients. The Pharma Biotech & Nutrition segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems.
Further Reading: What are earnings reports?
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.